Formation Bio
Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug candidates from pharma, universities, and biotech firms and develops them faster through a proprietary technology platform. The company integrates AI tools across drug selection, development strategy, and automated clinical trial execution to accelerate timelines and improve efficiency. Its platform includes AI Drug Hunter for asset selection and AI Drug Developer for R&D planning.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$608MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$528M across 2 disclosed rounds
+13$372M · Series D
Announced Jun 2024
Disclosed cumulative: $528M
Reported total $608M
Incomplete round history. $80M of the $608M reported total isn’t matched to a known round.
Founders
Product
Problem
Despite advances in drug discovery, bringing a new drug to market remains a decade-long, billion-dollar endeavor. The number of discovered drug candidates has doubled over the past decade, yet annual drug approvals have remained roughly flat, creating a widening gap between the backlog of known potential treatments and the few products that actually reach patients. The existing drug development ecosystem cannot keep pace with the rate of scientific discovery, leading to higher drug and healthcare costs and reduced treatment accessibility.
Solution
Formation Bio is a tech-driven pharmaceutical company that acquires clinical-stage drugs from pharma, universities, and biotech firms and develops them faster and more efficiently using a proprietary AI-native platform. The company integrates AI tools across the entire development lifecycle, from identifying and acquiring promising assets to optimizing clinical trial design and execution. By combining a multidisciplinary team of pharma and tech experts with advanced AI systems, Formation Bio aims to drive faster, more precise, and more efficient progress in bringing new treatments to patients. The platform includes AI Drug Hunter for asset selection, AI Drug Developer for R&D strategy, and Automated Clinical Trial capabilities to streamline trial processes, enabling the company and its partners to reach value inflection points earlier than industry norms.
Target Audience
Formation Bio primarily targets pharmaceutical companies, biotech firms, and universities seeking to accelerate the development and commercialization of clinical-stage drug candidates. The company also serves patients seeking access to cutting-edge treatments through participation in clinical trials.
Features
- AI Drug Hunter: Systematically identifies unmet needs and forecasts the potential of new drug opportunities through therapeutic landscape analysis, ROI modeling, indication mapping, knowledge graphs, and real-time intelligence.
- AI Drug Developer: Provides AI-driven guidance across regulatory planning, protocol drafting, and key cross-functional areas, enabling predictive planning, scenario modeling, and AI-generated trial designs.
- Automated Clinical Trial: Reduces manual work, accelerates timelines, and improves trial quality through automated study startup, AI-optimized recruitment strategies, and intelligent validation and monitoring.
- Proprietary tech-driven platform: Integrates interconnected data and AI tools to redefine how assets are sourced, evaluated, and developed.
- Flexible structures and financing pathways: Enables the acquisition and development of clinical-stage drugs from pharma, universities, and biotech, including the use of asset-centric "NewCo" structures that pair dedicated capital with development capabilities.